One in two women with advanced ovarian cancer has an HRD-positive tumor
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
Collaboration supports multiple discovery efforts, including vaccines
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Advancing to IND-enabling studies with multiple drug candidates
Subscribe To Our Newsletter & Stay Updated
